Executive record

Richard C. Pfenniger, Jr.

Director at Fluent, Inc.

Follow
More
Challenge a Claim

Alpha ID: alpha:person:richard-c-pfenniger-jrVersion: public-0As of: 2026-09-28

Not yet claimed13 published Claims7 sources
  • Director

Key Claims

Biography

Mr. Pfenniger is a private investor who previously served as Chief Executive Officer and President of Continucare Corporation and Chief Operating Officer of IVAX. He has extensive legal and pharmaceutical industry experience.

Alpha editorial summary written from the cited sources below. It does not change any Claim on this record.

Board service

Boards

Claims

Executive career

  1. 2026 to end not publishedExecutive title: Director · Organization not publishedCOCP 10-K executive officers

Claims

Conflicts and accountability

Alpha has not published independence, related-party, proceedings or disciplinary Claims for this record. This is not a finding that none exist.

Only disclosed facts and public registers appear here. Executive records carry no credit, personal litigation, background screening or underwriting views. None observed is not a clearance.

Evidence, history and coverage

Additional published Claims

Published evidence records

7 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.

  1. COCP 10-K executive officers

    sec filing · Source published: Mar 31, 2026 · Retrieved: May 16, 2026

    Supports 6 claims
    • AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: May 16, 2026
    • Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 16, 2026
    • Executive company: Executive at Cocrystal Pharma, Inc. · Claim reviewed: May 16, 2026
    • Executive title: Executive title: Director · Claim reviewed: May 16, 2026
    • Other Company Role: Richard C. Pfenniger, Jr. is also linked to OPKO Health, Inc. as Director. · Claim reviewed: May 16, 2026
    • Technology background: Technology background: not identified in the cited filing · Claim reviewed: May 16, 2026

  2. COCP DEF 14A director slate

    sec filing · Source published: May 5, 2025 · Retrieved: May 15, 2026

    Supports 2 claims
    • Board role: Board role: Director · Claim reviewed: May 15, 2026
    • Committee assignments: Committee assignments: Compensation, Corporate Governance and Nominating · Claim reviewed: May 15, 2026

  3. Open source

    sec proxy · Source published: May 5, 2025 · Retrieved: Apr 28, 2026

    Supports 1 claim
    • Professional Role: Director at Cocrystal Pharma, Inc. · Claim reviewed: May 16, 2026

  4. FLNT DEF 14A director slate

    sec filing · Source published: Apr 25, 2025 · Retrieved: May 15, 2026

    Supports 5 claims
    • AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: May 16, 2026
    • Board role: Board role: Director · Claim reviewed: May 15, 2026
    • Committee assignments: Committee assignments: Nominating/Governance · Claim reviewed: May 15, 2026
    • Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 16, 2026
    • Technology background: Technology background: not identified in the cited filing · Claim reviewed: May 16, 2026

  5. Open source

    sec proxy · Source published: Apr 25, 2025 · Retrieved: Apr 28, 2026

    Supports 1 claim
    • Professional Role: Director at Fluent, Inc. · Claim reviewed: May 16, 2026

  6. Open source

    public source · Source published: Date unavailable · Retrieved: Date unavailable

    Supports 1 claim
    • Board membership: Serves on the board of Fluent, Inc. · Claim reviewed: May 16, 2026

  7. Open source

    public source · Source published: Date unavailable · Retrieved: Date unavailable

    Supports 1 claim
    • Board membership: Serves on the board of Cocrystal Pharma, Inc. · Claim reviewed: May 16, 2026